These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23254686)

  • 1. Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients.
    Ingrosso G; Fantini M; Nardi A; Benvenuto M; Sacchetti P; Masuelli L; Ponti E; Frajese GV; Lista F; Schillaci O; Santoni R; Modesti A; Bei R
    Oncol Rep; 2013 Mar; 29(3):1167-74. PubMed ID: 23254686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients.
    Benvenuto M; Sileri P; Rossi P; Masuelli L; Fantini M; Nanni M; Franceschilli L; Sconocchia G; Lanzilli G; Arriga R; Faggioni G; Lista F; Orlandi A; Manzari V; Gaspari AL; Modesti A; Bei R
    J Transl Med; 2015 Mar; 13():101. PubMed ID: 25889931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies reactive with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy.
    Bednarczuk T; Stolarski C; Pawlik E; Slon M; Rowinski M; Kubota S; Hiromatsu Y; Bartoszewicz Z; Wall JR; Nauman J
    Thyroid; 1999 Mar; 9(3):289-95. PubMed ID: 10211607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
    Nakajima K; Heilbrun LK; Hogan V; Smith D; Heath E; Raz A
    Oncotarget; 2016 Dec; 7(50):82266-82272. PubMed ID: 27741512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimotos thyroiditis patients.
    Bei R; Mentuccia D; Trono P; Trono P; Masuelli L; Cereda V; Palumbo C; Marzocchella L; Mrozek MA; Pallotta P; Di Lella G; Modesti M; Cerilli M; Frajese GV; Frajese G; Zambruno G; Modesti A
    Int J Immunopathol Pharmacol; 2006; 19(3):661-74. PubMed ID: 17026851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice.
    Marzocchella L; Sini V; Buonomo O; Orlandi A; Masuelli L; Bonanno E; Lista F; Turriziani M; Manzari V; Roselli M; Modesti A; Bei R
    Cancer Sci; 2011 Mar; 102(3):509-15. PubMed ID: 21175994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum.
    Gonzalez-Gronow M; Cuchacovich M; Llanos C; Urzua C; Gawdi G; Pizzo SV
    Cancer Res; 2006 Dec; 66(23):11424-31. PubMed ID: 17145889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
    Nesslinger NJ; Ng A; Tsang KY; Ferrara T; Schlom J; Gulley JL; Nelson BH
    Clin Cancer Res; 2010 Aug; 16(15):4046-56. PubMed ID: 20562209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.
    Nakajima K; Heilbrun LK; Smith D; Hogan V; Raz A; Heath E
    Oncotarget; 2017 Mar; 8(11):17643-17650. PubMed ID: 27741522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
    Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
    Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
    Lokant MT; Naz RK
    Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
    Cavacini LA; Duval M; Eder JP; Posner MR
    Clin Cancer Res; 2002 Feb; 8(2):368-73. PubMed ID: 11839651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
    Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
    J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer.
    McNeel DG; Nguyen LD; Storer BE; Vessella R; Lange PH; Disis ML
    J Urol; 2000 Nov; 164(5):1825-9. PubMed ID: 11025777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
    Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
    J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IgG to heat shock proteins and Porphyromonas gingivalis antigens in diabetic patients with periodontitis.
    Sims TJ; Lernmark A; Mancl LA; Schifferle RE; Page RC; Persson GR
    J Clin Periodontol; 2002 Jun; 29(6):551-62. PubMed ID: 12296783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antibodies to blood group A predict survival on PROSTVAC-VF.
    Campbell CT; Gulley JL; Oyelaran O; Hodge JW; Schlom J; Gildersleeve JC
    Clin Cancer Res; 2013 Mar; 19(5):1290-9. PubMed ID: 23362327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
    Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.